Lantibio Report issue

For profit Phase 3
Founded: Chapel Hill NC United States (1997)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2006
NCT00599716
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Alternative names

River Plate Biotechnology, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

hyaluronic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1